NEW YORK, Sept. 28 - Aptus Genomics, a biotech company that focuses on G-protein coupled receptor genes, has appointed Krystyna Belendiuk as president, the company said on Friday.
"I am very pleased to have someone with Krystyna's knowledge and experience join the Aptus management team," Kevin Chance, founder and CEO of Aptus, said in a statement.
Before joining Aptus, Belendiuk was co-founder, director, and senior vice president of Pharmavene, now known as Shire Laboratories.
Aptus, which in June moved its headquarters to Gaithersburg, Md., from Rockville, Md., reported in May that it raised $6.2 million in a round of financing.
The company, founded in June 2000, is currently completing gene collection and will move to high-throughput functional assays and screening to be used for in-house drug discovery development and future partnership collaborations, Chance told GenomeWeb in May.